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Introduction
Hydrofluoric acid (HF) is widely used for the manufac-
ture of fluorinated organic compounds, inorganic fluo-
rides,  uranium  treatment,  fluorocarbon  products,  and 
fluoropolymers and derivatives. HF is also used in the 
metal industry for scouring and shining steels (especially 
for stainless steel products) and other metals (such as for 
pickling titanium), in the oil refinery industry (catalyst 
for alkylation), in electronics (for the surface treatment 
of semiconductor components), in the glass industry (for 
engraving, etching, frosting, and polishing of glass and 
crystal, and for quartz purification), in construction (for 
facade cleaning), in the chemical industry (particularly 
in  laboratories),  in  the  refrigeration  industry,  and  in 
the photovoltaic industry (polysilicones, fluoropolymer 
films).  Dilute  HF  (usually  6–13%)  has  household  uses 
such as rust stain removal, aluminum cleaning and pol-
ishing  (for  automobile  wheels),  and  for  colored  wood 
cleaning.
The worldwide production of HF is increasing with >1 
million tons per year (including US production capac-
ity of about 434,000 tons in 2002 [1] plus 480,000 tons 
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imported [2] and Chinese production capacity of about 
870,000 tons in 2008 [3]).
HF  is  a  particularly  dangerous  acid  due  to  its  two 
properties: corrosiveness and toxicity. In addition, as it is 
only partially dissociated (pKa = 3.2), this small molecule 
is capable of penetrating deeply into tissues.
HF is an acid that induces severe tissue necrosis and 
is a serious systemic poison due to two mechanisms of 
ion delivery: a corrosive hydrogen ion (H+) associated 
with cutaneous and mucous membrane lesions [4] and 
with ocular [5] and respiratory tract [6–8] damage; a toxic 
fluoride ion (F−) with slower onset local and systemic 
effects  (especially  decreased  myocardial  contractility 
and cardiac arrhythmias such as tachycardia, torsades de 
pointes ventricular tachycardia, and ventricular fibrilla-
tion [9]), with potentially lethal effects [10–14].
The F− ion chelates calcium and magnesium [15] form-
ing insoluble salts: CaF2 and MgF2. Soluble salts such as 
NaF and KF are also produced and act at high concentra-
tions as direct cellular poisons.
This  chelation  induces  metabolic  disorders  [16,17] 
that lead to delayed cellular death and secondary tissue 
necrosis.  Moreover,  the  binding  of  calcium  is  thought 
to increase cell membrane permeability to potassium, 
resulting  in  neuronal  depolarization  and  intense  pain 
[18,19]. Fluoride ion is also known to attack enzymes and 
cell membranes [20].
The systemic consequences of HF are due to increased 
fluoride concentrations in the body, which can modify 
the blood levels of calcium (hypocalcemia), magnesium 
(hypomagnesemia),  and  potassium  (hyperkalemia) 
[21–23]. HF in concentrations of 50% or greater (includ-
ing  anhydrous  hydrogen  fluoride)  causes  immediate, 
severe, throbbing pain, and a whitish discoloration of the 
skin, which usually forms blisters. HF concentrations of 
20–50% may produce pain and swelling, which may be 
delayed in onset for up to 8 h. HF solutions of <20% cause 
almost no immediate pain but may cause delayed seri-
ous skin injury 12–24 h later [24] (Table 1). Especially in 
the case of prolonged exposure to very dilute solutions, 
symptoms  may  even  be  delayed  in  onset  for  several 
days.
The systemic toxicity is potentially life-threatening [25] 
depending on the available total amount of free fluoride 
ions that penetrate into the body. Lethal risk is correlated 
with the HF concentration, the total body surface area 
(TBSA) exposed, and the duration of contact [26].
Study objectives
This study was performed to demonstrate the extent of 
epidermal  and  dermal  lesions  following  contact  with 
70% HF on living human skin explants ex vivo and to 
compare the efficacy of different decontamination wash-
ing protocols.
Observation of the general morphology allowed char-
acterization of the nature and extent of 70% HF-induced 
skin lesions at the tissue and cellular levels over time 
following  exposure  alone  or  exposure  followed  by 
decontamination.
Comparison  of  two  different  washing  protocols 
was  done:  running  tap  water  followed  by  a  one-time 
calcium  gluconate  (CaG)  gel  topical  application,  and 
Hexafluorine®  (a  specific  active  HF  decontamination 
solution).
Methods
The  study  was  performed  at  BIO-EC  Laboratories, 
Longjumeau,  France  in  accordance  with  a  previously 
described  and  established  experimental  burn  model 
using human skin explants ex vivo (see Part 1).
Tested products:
70% HF (FLUKA Ref. 47610, batch 7125A, with an  1. 
exactly titrated concentration of 73.0%)
Running tap water 2. 
CaG gel with topical application of 1 mg/cm 3.  2 (KAYS 
MEDICAL, Lot F022011/09, 2.5% gel)
Hexafluorine 4.  ®  spray  (miniDAP  200 mL,  batch 
971201C, Prevor Laboratory, Valmondois, France).
Explants preparation
The  70  human  skin  explants  utilized  were  prepared 
from  donated  skin  from  an  elective  abdominoplasty 
from  a  35-year-old  woman  (Reference  P556).  Verbal-
informed consent was obtained (see Part 1 for details of 
the informed consent procedure). The diameter of each 
explant was ~10 mm. The study was performed in trip-
licate to insure the internal consistency of the method, 
not for statistical purposes. The explants were preserved 
alive in BEM medium (BIO-ECs Explant Medium batch 
No. 071107) at 37°C in a moist atmosphere containing 
5% CO2 for 12–15 hours before the study began. These 
explants were divided into four groups (Table 2).
Application of products and washing solutions
The  HF  solution  was  applied  topically  to  the  explants 
of  groups  F  (70%  HF;  no  washing),  FWCaG  (70%  HF; 
water  washing  +  topical  CaG);  and  FHexa  (70%  HF; 
Hexafluorine®  washing)  by  deposition  on  filter  paper 
disks  (9 mm  diameter;  MEDIAS  FILTRANS  DURIEUX 
S.A., papier filtre No. 268) previously saturated with 30 µL 
(47 µL/cm2) of 70% HF solution.
For group F, HF was left in contact with the skin for 
20 sec and then the filter paper disks were removed. No 
washing  was  done.  After  the  HF-saturated  disks  were 
removed,  sampling  for  histological  observations  was 
done at 5, 10, 15, and 30 min, 1, 2, and 4 h, and 24 h.
For groups FWCaG and FHexa: after 20 sec of con-
tact, the disks were removed. Then the different washing 
Table 1.  Pain and skin lesions: depending on HF concentration.
Pain and Skin lesions Concentration of HF
Immediate pain and rapid necrosis 50% or greater
Delayed pain and burn 1–8 h 20–50%
Delayed pain and necrosis until 24 h ≤20%110  F. Burgher et al.
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protocols were performed. The explants of group FWCaG 
were washed with running tap water for 15 min (~2000 mL 
per explant), and then topical CaG gel (2.5%) was applied, 
one time only, to each explant at a dose of 1 mg/cm2. The 
explants of group FHexa were washed with Hexafluorine® 
applied as a spray of 400 mL over ~10 min. Group T (neg-
ative controls) did not receive any treatment. The total 
observation time ranged from 20 sec to 24 h.
Histology sampling
Group T (negative controls): At the beginning of the study 
(T0), two explants of the control group were sampled and 
fixed in Bouin’s solution. Two other explants were sam-
pled and similarly fixed at each sampling time: 20 sec, 5, 
10, 15, and 30 min, 1, 2, and 4 h, and 24 h.
Group  F  (positive  controls):  Twenty  seconds  after 
the beginning of the 70% HF application, two explants 
from group F were sampled and fixed immediately after 
removal of the saturated disk. Then, two explants were 
sampled and fixed in the same manner at each of the 
sampling times: 5, 10, 15, and 30 min, 1, 2, and 4 h, and 
24 h.
Groups  FWCaG  and  FHexa:  Five  minutes  after  the 
washing step, two explants from each of groups FWCaG 
and FHexa were sampled and fixed in Bouin’s solution. 
Then two explants from each group were sampled and 
fixed in the same manner at each of the sampling times: 
10, 15, and 30 min, 1, 2, and 4 h, and 24 h.
Histology
Tissue fixation, sample preparation, and histology proce-
dures are described in detail in Part 1.
Alterations  of  cellular  structures  were  searched  for 
during  penetration  of  HF  through  the  main  skin  lay-
ers:  upper  epidermis  (stratum  corneum  +  lucidum  + 
granulosum), basal epidermis (stratum germinativum), 
and papillary and reticular dermis.
Results
Group  T  (no  HF  exposure;  no  washing  of  explants—
negative controls): At T0, the skin showed four to five 
cellular  sites  with  good  morphology.  In  the  papillary 
and  the  lower  reticular  dermis,  the  cellular  structures 
had good morphology. Whatever the time of survival, no 
modifications  of  the  epidermal  and  dermal  structures 
were observed up to 24 h. (Please refer to Part 1, Figure 2 
for the histological appearance of normal control explant 
skin.)
Group F (explants exposed to 70% HF for 20 sec on fil-
ter paper disks, which were then removed; no washing—
positive controls)
After 20 sec of contact, no deterioration of the struc-
tures of either the epidermis or dermis was observed. At 
5 min after a 20-sec exposure, very clear cellular deterio-
ration was observed in the epidermis and papillary and 
reticular dermis. Lesions clearly increased at 10, 15, and 
30 min and 1 h after a 20-sec exposure, with the marked 
appearance  of  coagulation  necrosis  including  acido-
philic cytoplasm and pyknotic nuclei throughout all the 
skin layers. At 24 h after a 20-sec exposure, the epidermis 
  presented  completely  necrotic  structures.  The  lesions 
were less intense in the papillary and reticular dermis 
(Figure 1A and 1B).
Group FWCaG (explants exposed to 70% HF for 20 sec 
on filter paper disks, which were then removed and the 
explants were rinsed with running tap water followed by 
one topical application of 2.5% CaG gel).
At 5 and 10 min after a 20-sec exposure, no deteriora-
tion of the structures of either the epidermis or dermis 
was observed.
At 15 min after a 20-sec exposure, very clear cellular 
deteriorations  appeared  in  the  epidermis  and  in  the 
papillary  and  reticular  dermis.  These  were  decreased 
at 30 min, and were no longer observed after 1 and 2 h 
after a 20-sec exposure. Slight edematous changes were 
visible  in  the  epidermal  basal  layers  at  4 h  and  these 
were clearly increased at 24 h after a 20-sec exposure 
(Figure 2A and 2B).
Group FHexa (explants exposed to 70% HF for 20 sec 
on  filter  paper  disks,  which  were  then  removed  and 
the  explants  washed  with  Hexafluorine®  for  ~10 min 
(400 mL)).
At 5, 10, 15, and 30 min and 1, 2, 4, and 24 h after a 
20-sec  exposure,  no  deterioration  of  the  structures  of 
either the epidermis or dermis was observed. Washing 
by spraying Hexafluorine® for ~10 min (400 mL) gave a 
homogeneous result on the explants. Whatever the time 
of observation, no burn lesions were observed (Figure 3A 
and 3B).
Table  3  summarizes  the  results  of  the  observations 
for all study groups and for each of the three main skin 
explant layers: epidermis, papillary dermis, and reticular 
Table 2.  Explants and treatment groups.
Group
Number  
of Explants Treatment
Histological 
sampling Times
T 20 None T0, 20 s, 5, 10, 
15, 30 min, 1, 2, 4 
and 24 h
F 18 30 µL (47 µL/cm2) 
70% hydrofluoric acid 
exposure without 
washing
20 s, 5, 10, 15, 
30 min, 1, 2, 4, 
and 24 h
FWCaG 16 30 µL (47 µL/cm2) 
70% hydrofluoric acid 
applied for 20 s, then 
washing with water 
+ calcium gluconate 
topically
After the end of 
washing at: 5, 
10, 15, 30 min, 1, 
2, 4, and 24 h
FHexa 16 30 µL (47 µL/cm2) 
70% hydrofluoric 
acid applied for 20 
s, then washing with 
Hexafluorine®  
(2 washes with 200 mL 
each per explant)
After the end of 
washing at: 5, 
10, 15, 30 min, 1, 
2, 4, and 24 h
In all treatment groups, 70% HF saturated filter paper disks were 
left in contact for 20 s and then removed.HF human skin explants decontamination  111
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dermis. It makes it possible to follow the evolution of the 
tissue lesions following a 20-sec cutaneous exposure to 
70% HF and, indirectly, to make a correlation with the 
overall kinetics of HF penetration through human skin 
explants  layers.  It  also  allows  comparison  of  human 
skin explants exposed to 70% HF and either not washed 
or washed with different washing protocols. As can be 
appreciated, water washing followed by application of 
topical CaG gel did delay the onset of burn lesions and 
mitigated their severity compared with positive controls 
(70% HF; no washing), when the explants were washed 
with Hexafluorine®, no burns developed and there were 
no differences in the histological appearance from those 
of the untreated negative control group.
Discussion
HF burns have specific pathophysiological mechanisms 
that  require  specialized  treatment  to  prevent  serious 
sequelae.  Appropriate  urgent  first  aid  and  secondary 
medical management can improve the prognosis. Initial 
decontamination must be efficacious to avoid or mini-
mize the extent (TBSA) and depth of HF burns and to 
prevent systemic absorption and distribution of the F− 
ions responsible for potential life-threatening systemic 
toxicity [27]. Efficacious washing must attempt to arrest 
the progression of injury, but obviously cannot reverse 
tissue necrosis that has already occurred.
Up to now (see Part 1), there has been a lack of his-
tological studies allowing real-time observation of cel-
lular  damage  during  penetration  of  concentrated  HF 
into human skin, as well as real-time observation of how 
different  decontamination  measures  may  affect  such 
penetration and potential skin injury.
In a previous study (see Part 1), human skin explants 
exposed ex vivo to 70% HF were tested. It was shown with 
topical exposure to 30 µL (47 µL/cm2) of 70% HF, 20 sec of 
contact was sufficient to penetrate the upper layers of the 
skin explants. By 5 min after a 20-sec 70% HF exposure, 
all the epidermal and dermal layers of the skin were dam-
aged, but not totally and irreversibly destroyed.
In this study, it was not a question of the treatment of 
fully developed HF skin burns, as has been done previously 
in a rat model [28]. Rather, it was a question of which ini-
tial decontamination measures are most likely to prevent 
or mitigate the effects of HF human skin exposure. Such 
initial measures using water washing are described in 
the ANSI/ISEA Z358.1-2009 American National Standard 
for Emergency Eyewash and Shower Equipment. There 
are  similar  measures  noted  in  the  European  Norms 
(European  Committee  for  Standardization:  NF  EN 
15154-3; June 06, 2009).
The present study was carried out in conditions such 
as to be as close as possible to potential exposure to high 
concentrations of HF likely to be encountered in indus-
trial settings.
Explants  from  the  control  group  remained  alive 
during the 24 h of the experiment. Seventy percent HF 
penetrated  human  skin  explants  after  20 sec  of  expo-
sure. Without decontamination washing, the first cel-
lular alterations were noticeable by 1 min after a 20-sec 
exposure. The reticular dermis was reached and injured 
by 5 min after a 20-sec exposure. At 5 min after a 20-sec 
exposure, a massive attack of all the cutaneous layers 
was already present. The lesions then remained stable 
between 10 min and 4 h. At 24 h after a 20-sec exposure, 
the epidermis was totally necrotic while the dermis was 
clearly  altered  (appearance  of  coagulation  necrosis 
including pyknotic nuclei and totally acidophilic cyto-
plasm). Similar observations were reported by Ohtani 
et al. [29] in a human case report with 60% concentration 
HF lethal chemical burns.
Figure  3.  (A)  and  (B)  HF-exposed  explants  rinsed  with 
Hexafluorine®; aspect at 24 h after a 20-sec exposure. Epidermis 
(A) and dermis (B). No deterioration of the structures of either 
the epidermis or dermis was observed. (See colour version of this 
figure online at www.informahealthcare.com/cot)
Figure 1.  (A) and (B) Exposed 70% HF, nonwashed explants, aspect 
at 24 h after a 20-sec exposure. Epidermis (A) and dermis (B). At 
24 h after a 20-sec exposure, the epidermis presented completely 
necrotic structures with the appearance of coagulation necrosis. 
The lesions were less intense in the papillary and reticular dermis 
(See colour version of this figure online at www.informahealthcare.
com/cot)
Figure 2.  (A) and (B) HF-exposed explants rinsed with water + 
CaG, aspect at 24 h after a 20-sec exposure. Epidermis (A) and 
dermis (B). Edematous changes were visible in the epidermal basal 
layer at 24 h after a 20-sec exposure. An appearance of coagulation 
necrosis including pyknotic nuclei and acidophilic cytoplasm was 
noted in the papillary dermis. These changes were less apparent 
in the reticular dermis. (See colour version of this figure online at 
www.informahealthcare.com/cot)112  F. Burgher et al.
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In  the  past,  water  washing  was  a  great  advance  in 
the first-aid care for victims of corrosive skin exposures. 
Historically, evidence for the seriousness of HF burns and 
the need for efficacious first-aid measures was initially 
described in France by Thénard and Gay Lussac [30] in 
the first quarter of the 19th century.
At this early date, these authors had already noted that 
the development of HF burns can sometimes be slowed 
and that the appearance of the lesions could be delayed in 
onset from 1 to 8 h after exposure. They also experienced 
the acute pain sensation which “can avoid sleeping and 
induce fever” [30]. Thénard and Gay Lussac experimented 
upon themselves and discovered that a dilute solution of 
potassium hydroxide was able to stop the development of 
HF burns and could alleviate the pain sensation due to its 
chemical activity against the corrosive effects of HF. For 
unknown reasons, this interest in the concept of active 
HF decontamination was lost until the mid-1960s.
At that time, passive decontamination with copious 
prolonged water washing was and has continued to be 
recommended. Using water washing immediately after 
skin  exposure  allows  dilution  and  mechanical  rinsing 
of the HF from the skin. However, water washing alone 
is not always sufficient for preventing or minimizing HF 
burn injuries, especially with exposure to high concen-
trations of HF and/or large TBSA exposures.
A number of case reports show that HF burn victims 
have required surgical treatments and that others have 
died within a short time after exposure to concentrated 
HF, despite immediate copious water washing. Fatalities 
have occurred with exposure to highly concentrated HF 
(i.e. anhydrous HF) with only a small TBSA exposure on 
thin and highly vascularized skin such as that on the face 
and in the genital area [31–34].
A more theoretical approach to HF decontamination 
reveals that the first few seconds to minutes of washing 
Table 3.  Schematic summary of the histological results for all the groups and for each skin layer.
Time of exposure and skin layers
T (Control untreated group)  
20 explants
F (HF without 
washing) 18 explants
FWCaG (HF + water 
washing + calcium 
gluconate) 16 explants
FHexa (HF + 
Hexafluorine® 400 mL) 
16 explants
T0 Epidermis GM = good morphology GM GM GM
Papillary dermis
Reticular dermis
20 s Epidermis
Papillary dermis
Reticular dermis
5 min Epidermis PN + AC
Papillary dermis
Reticular dermis PN + CA moderately
10 min Epidermis PN= pyknotic 
nucleiAC = acidophilic 
cytoplasm
Papillary dermis
Reticular dermis
15 min Epidermis PN + AC moderately
Papillary dermis PN + AC
Reticular dermis
30 min Epidermis Some necrotic cells
Papillary dermis GM
Reticular dermis
1 h Epidermis
Papillary dermis
Reticular dermis
2 h Epidermis
Papillary dermis
Reticular dermis
4 h Epidermis Slightly edematous cells 
with mild acantholysis
Papillary dermis GM
Reticular dermis
24 h Epidermis Totally necrotic Very edematous cells 
with a very clear 
cytoplasm
Papillary dermis PN + AC PN + AC
Reticular dermis Lesser alterations
GM, good morphology; PN, pyknotic nucleus; AC, acidophilic cytoplasm.
PN and AC are described as part of the appearance of coagulation necrosis.
In all treatment groups, 70% HF saturated filter paper disks were left in contact for 20 s and then removed.HF human skin explants decontamination  113
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are critical to prevent or minimize the development of 
HF skin burns. Some authors have therefore suggested 
a shorter initial water washing duration [24,35,36]. Segal 
[24] suggests that the duration of water washing should 
be limited to 5 min when a specially prepared iced ben-
zalkonium chloride solution or CaG gel is available. The 
concept of an efficacious active initial washing for HF 
exposures is derived from this approach. Water has no 
active binding or chelating properties for any chemical 
substance and does not inactivate either of the skin tissue 
injury mechanisms of HF. As water is hypotonic, it can-
not be expected to stop penetration of HF throughout all 
layers of the skin and may, in fact, enhance such penetra-
tion. Schrage et al. [37] have demonstrated that cellular 
damage following exposure to a corrosive substance is 
actually  enhanced  in  healthy  corneal  cell  cultures  by 
hypo-osmolar washing with tap water. Faced with the 
limitations [38] of water washing and based on theoreti-
cal concepts of active decontamination, an approach that 
allows deactivation of both HF’s corrosive and local toxic 
potential is logical.
Free fluoride ions play a key role in local tissue toxicity, 
as well as in systemic toxicity. Therefore, improvement of 
first-aid measures for HF exposures initially focused only 
on the F− ion. Studied and published protocol changes to 
improve the outcome of HF burns only considered mea-
sures to be done after water washing [39]. Very few such 
studies considered acid (H+) neutralization and F− chela-
tion as the initial first-aid measures after HF exposure 
[40].
Topical CaG was first considered for binding F− ions 
and  interfering  with  their  chelation  of  tissue  calcium. 
The  first  publication  describing  HF  burn  therapy  with 
CaG dates from 1964 [41]. At the current time, CaG is the 
product most often used worldwide for secondary care 
of HF burns. Various application/administration proto-
cols have been proposed. Repeated topical application 
by inunction of 2.5–5.0% CaG gel (massaging the gel into 
the burn site seems to increase skin penetration over a 
24-h period) or continuous ointment application (such 
as inside an over-large surgical glove for finger or hand 
exposures). As the CaG-F− ion chelation property may be 
insufficient to reach F− ions that have already penetrated 
deeply  into  the  skin  tissues,  subcutaneous  injection 
has been proposed to improve efficacy [29]. The skin is 
infiltrated with CaG underneath the burned area and the 
immediately adjacent skin. The usual dose is limited to 
0.5 mL/cm2 skin surface area of a 5% or 10% CaG solution 
(with a maximum of 0.5 mL per digit for finger burns). 
Care must be taken not to use calcium chloride solution 
in this manner because it can itself cause significant local 
tissue necrosis and sloughing. Pain that is not relieved or 
recurs is a clinical indication for further CaG infiltration.
Both intravenous and intra-arterial infusion of CaG 
can be done to treat systemic toxicity or hand/foot burns. 
These exposure routes are indicated for systemic toxic-
ity signs and symptoms, or for more extensive HF burns 
or burns not responding to topical or subcutaneous CaG 
treatment  [21,34,42–45].  Either  CaG  or  calcium  chlo-
ride may be infused intravenously, but only CaG may 
be  infused  intra-arterially.  An  intravenous  Beir-block 
technique may also be used for HF extremity burns [46]. 
Intra-arterial infusion of CaG can have adverse effects 
such as arterial spasm and local bleeding [47].
Williams et al. [48] showed that 2.5% CaG significantly 
reduced burn size as early as 1 h after a single applica-
tion on the shaved hind legs of rats burned with 70% 
HF. Magnesium sulfate has also been recommended for 
topical application, infiltration, or infusion [49–53]. Some 
authors have proposed that CaG be combined with dim-
ethyl sulfoxide (DMSO) as a solvent vehicle to improve 
the calcium penetration, especially for nail or nail bed 
exposures [25,54].
Algorithms for HF splash victim management were 
studied by Kirkpatrick et al. (1995) [54], using 2.5% CaG 
gel topically and oral CaG tablets before admission to 
hospital, and intravenous infusion of 20 mL of 10% CaG 
solution under medical supervision after hospital admis-
sion. Dünser et al. [26] have also provided concise recom-
mendations for therapy of major HF burns. Ohata et al. 
[55] described seven cases in which relief of severe pain 
occurred with CaG therapy. Nguyen et al. [43] described 
an unusual case where carotid intra-arterial infusion of 
CaG was used successfully to treat facial HF burns [43].
In the present study, a 15-min tap water washing fol-
lowed by a single topical application of 2.5% CaG gel in 
one intervention leg was utilized to be consistent with 
common currently recommended first-aid measures.
In the FWCaG group, after 20 sec of exposure to 70% 
HF and then washing with tap water for 15 min followed 
by a single topical application of 2.5% CaG gel, a tempo-
rary delay in the onset of the appearance of tissue lesions 
was observed. The histological effects only became vis-
ible after 15 min, in comparison with the exposed but 
not washed control group in which the explants showed 
evidence of damage in all tissue layers after 5 min. In 
addition, in the FWCaG group, there was a resumption 
of evolution of the tissue lesions after 4 h. At 24 h (at the 
conclusion of the experiment), HF chemical lesions were 
clearly present, though not as severe in the exposed but 
not washed control group.
As the tissue lesions continued to evolve from 4 to 24 h, 
this provides support for recommendations for repeated 
application of topical CaG. As well, in some cases topical 
CaG may need to be supplemented or replaced with par-
enteral  CaG  administration  (subcutaneous  infiltration, 
intravenous or intra-arterial injection, or use of a Bier 
block technique for extremity burns).
When  the  results  in  the  FHexa  group  of  explants 
(exposed  to  70%  HF  for  20 sec  and  then  washed  for 
~10 min with 400 mL of Hexafluorine®), which developed 
no lesions at any sampling time, were compared with 
the  unexposed  and  not  washed  control  group  (group 
T), there were no differences in histological appearance 
at any sampling time from 5 min to 24 h after a 20-sec 
exposure. Compared with the FWCaG group (20 sec of 114  F. Burgher et al.
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70% HF exposure, then 15 min of tap water washing fol-
lowed by a single topical application of 2.5% CaG gel), the 
Hexafluorine® group developed no lesions at any sam-
pling time, washing with tap water followed by topical 
CaG only delayed the onset of the appearance of the HF 
lesions and decreased their severity. There results suggest 
that Hexafluorine® acts on both mechanisms of HF skin 
injury:  corrosiveness  and  local  toxicity.  Hexafluorine® 
deactivates the corrosive H+ ion and chelates the toxic F+ 
ion of HF. Moreover, it can prevent or minimize the pen-
etration of undissociated HF into the tissues because it 
is hypertonic and establishes an osmotic gradient away 
from the skin surface.
The experimental results presented here are in accor-
dance  with  published  clinical  results  regarding  the 
use of Hexafluorine® in over 30 cases of HF splashes in 
industrial settings [56,57] where no severe burns lesions 
developed, there was an absence of any sequelae, and 
a reduction in lost work time as compared with similar 
reported cases decontaminated with water. Five of these 
>30 cases involved HF exposure circumstances that were 
potentially life-threatening because of the HF concentra-
tion and the exposed body surface area. In these cases, 
rapid relief of pain was noted, not from any analgesic 
effect of Hexafluorine®, but most likely from inactivation 
of the HF, which prevented further tissue damage.
Some experimental studies with rats [28] have chal-
lenged Hexafluorine® efficacy, but only when the HF had 
been left in contact with the skin long enough to result in 
tissue cellular death before Hexafluorine® was applied. 
As Hexafluorine® is a decontamination solution and not 
a treatment for already establish necrotic HF burns, these 
results are not surprising. In contrast, in two studies, one 
an ex vivo rabbit cornea study using an Eveit® model com-
bined with a powerful OCT imaging technique, Rihawi 
et al. [58] and Spöler et al. [59] showed that Hexafluorine® 
was  a  more  efficacious  HF  decontamination  solution 
than either water or CaG ocular drops.
Water has a primary mechanical washing effect with 
an added minor diluting effect. As Hexafluorine® is pro-
vided as a solution in sterile water, these same washing 
and diluting effects are also present. However, as water 
has no chemical effect on HF, it apparently may leave a 
residue of fluoride ion on the skin in a sufficient quantity 
to explain the observed secondary necrosis.
Topical CaG has the properties of chelating free fluo-
ride ions, thereby decreasing their concentration in the 
injured tissue. It can also provide a source of extracellular 
calcium, which can change the balance between extra-
cellular and intracellular calcium. In the study presented 
here,  a  single  application  of  CaG  gel  following  water 
washing was not sufficient to prevent the delayed devel-
opment of tissue damage.
Amphoteric Hexafluorine®, in contrast, acts to neu-
tralize the H+ ion and chelates the F− ion, thereby actively 
acting  against  both  mechanisms  of  HF  cutaneous  tis-
sue injury. In the study presented here, no cutaneous 
tissue  injury  resulted  over  24 h  of  observation  from  a 
20-s application of 70% HF followed by Hexafluorine® 
washing.
Conclusion
As demonstrated in the utilized 70% HF-exposed human 
skin explants ex vivo, 70% HF can cause injury to all of 
the explant skin layers within 5 min after a 20-s applica-
tion. Decontamination with water followed by a single 
application of topical 2.5% CaG gel delayed the onset of 
the skin injury and mitigated the severity of the damage, 
but did not prevent injury in this experimental model. 
In  contrast,  when  the  HF-exposed  skin  explants were 
washed  with  Hexafluorine®,  no  tissue  injury  devel-
oped  during  24-h  observation.  Thus,  in  this  experi-
mental  model,  decontamination  with  Hexafluorine® 
completely prevented 70% HF cutaneous tissue injury. 
Hexafluorine® deserves consideration for further study 
and clinical application.
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